Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTHOTCMKTS:EVARFOTCMKTS:HDIINASDAQ:NMRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.00$0.15$0.16▼$1.57$6K4.024,068 shs3 shsEVARFLombard Medical$0.00$0.00▼$0.00$2KN/AN/AN/AHDIIHypertension Diagnostics$0.00+∞$0.00$0.00▼$0.00$5K1.24193,800 shs207,542 shsNMRDNemaura Medical$0.00$0.00▼$0.06$4K0.517,917 shs1 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%+33.33%-99.25%-99.34%-99.88%EVARFLombard Medical0.00%0.00%0.00%0.00%0.00%HDIIHypertension Diagnostics0.00%0.00%0.00%0.00%-50.00%NMRDNemaura Medical0.00%0.00%0.00%-50.00%-99.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVARFLombard MedicalN/AN/AN/AN/AN/AN/AN/AN/AHDIIHypertension DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ANMRDNemaura Medical0.99 of 5 stars0.03.00.04.50.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AEVARFLombard Medical 0.00N/AN/AN/AHDIIHypertension Diagnostics 0.00N/AN/AN/ANMRDNemaura Medical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.07N/AN/A($2.43) per share0.00EVARFLombard MedicalN/AN/AN/AN/AN/AN/AHDIIHypertension DiagnosticsN/AN/AN/AN/AN/AN/ANMRDNemaura Medical$3.02K0.00N/AN/A($0.41) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00∞N/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)EVARFLombard MedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AHDIIHypertension DiagnosticsN/AN/A0.00∞N/AN/AN/AN/AN/ANMRDNemaura Medical-$14.14M-$0.39N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AEVARFLombard MedicalN/AN/AN/AN/AN/AHDIIHypertension DiagnosticsN/AN/AN/AN/AN/ANMRDNemaura MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01EVARFLombard MedicalN/AN/AN/AHDIIHypertension DiagnosticsN/AN/AN/ANMRDNemaura MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%EVARFLombard MedicalN/AHDIIHypertension DiagnosticsN/ANMRDNemaura Medical4.41%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%EVARFLombard MedicalN/AHDIIHypertension Diagnostics40.00%NMRDNemaura Medical40.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableEVARFLombard Medical11116.19 millionN/ANot OptionableHDIIHypertension Diagnostics2,01752.39 million170.87 millionNot OptionableNMRDNemaura Medical4040.35 million24.04 millionNo DataEVARF, ARTH, HDII, and NMRD HeadlinesRecent News About These CompaniesNemaura Medical (OTC:NMRD) Stock Quotes, Forecast and News SummaryAugust 25, 2024 | benzinga.comNemaura Medical Inc (NMRD)May 26, 2024 | investing.comNXNN Nexeon Medsystems IncMay 24, 2024 | seekingalpha.comNemaura Medical Stock (OTC:NMRD) Earnings Dates and Earning CallsFebruary 23, 2024 | benzinga.comMaxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ETJanuary 22, 2024 | finance.yahoo.comNemaura Medical, Inc: Important Update on Listing Status and Strategic DirectionJanuary 3, 2024 | finanznachrichten.deImportant Update on Listing Status and Strategic DirectionJanuary 3, 2024 | finance.yahoo.comBuy Rating Affirmed for Nemaura Medical on sugarBEAT Prospects and Market ExpansionDecember 20, 2023 | markets.businessinsider.comNemaura Medical: Regulation Fd Disclosure, Financial Statements And ExhibitsDecember 15, 2023 | cbonds.comNemaura Medical, Inc: Nemaura Medical Inc. Receives Positive Nasdaq Listing DecisionDecember 13, 2023 | finanznachrichten.deNemaura Medical Inc. Receives Positive Nasdaq Listing DecisionDecember 13, 2023 | finance.yahoo.comNemaura Medical (NMRD) Price Target Increased by 54.55% to 8.67November 27, 2023 | msn.comNemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic GrowthNovember 21, 2023 | finance.yahoo.comNemaura (NMRD) to Expand in UK With Metabolic Health ProgramNovember 17, 2023 | msn.comNemaura Medical First Half 2024 Earnings: US$0.13 loss per share (vs US$0.33 loss in 1H 2023)November 16, 2023 | finance.yahoo.comNemaura Medical, Inc: Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business UpdateNovember 15, 2023 | finanznachrichten.deAcutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2MNovember 14, 2023 | seekingalpha.comNemaura Medical, Inc: Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss DrugsNovember 14, 2023 | finanznachrichten.deNemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss DrugsNovember 14, 2023 | finance.yahoo.comNemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsApple’s Quiet HomePad Delay Could Be Its Loudest Move YetBy Chris Markoch | June 1, 2025View Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetEVARF, ARTH, HDII, and NMRD Company DescriptionsArch Therapeutics OTCMKTS:ARTH$0.0012 0.00 (0.00%) As of 06/11/2025Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Lombard Medical OTCMKTS:EVARFLombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.Hypertension Diagnostics OTCMKTS:HDII$0.0001 +0.00 (+∞) As of 01:45 PM EasternHypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.Nemaura Medical NASDAQ:NMRDNemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
